BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/11/2015 1:33:00 PM | Browse: 554 | Download: 607
Publication Name World Journal of Gastroenterology
Manuscript ID 20414
Country/Territory China
Received
2015-06-04 09:30
Peer-Review Started
2015-06-06 17:18
To Make the First Decision
2015-07-13 15:22
Return for Revision
2015-07-17 16:55
Revised
2015-07-28 23:43
Second Decision
2015-09-12 22:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-09-14 11:35
Articles in Press
2015-09-14 11:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
2015-09-26 08:06
Typeset the Manuscript
2015-10-21 14:03
Publish the Manuscript Online
2015-11-11 13:34
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki and Wei Tang
Funding Agency and Grant Number
Corresponding Author Jian-Jun Gao, PhD, Department of Pharmacology, School of Pharmaceutical Sciences, Qingdao University, 38 Dengzhou Road, Qingdao 266021, Shandong Province, China. gaojj@qdu.edu.cn
Key Words Angiogenesis; Mammalian target of rapamycin; Extracellular-signal regulated kinase; Endothelial growth factor receptor; Histone deacetylases
Core Tip Cancer is regarded as a heterogeneous disease, with no exception of hepatocellular carcinoma (HCC), which requires combined chemotherapy. HCC is not sensitive to most currently used conventional cytotoxic drugs. The approval of sorafenib, a molecular targeted drug that inhibits RAF kinase and several other angiogenesis-related receptor tyrosine kinases, opens a door for systematic treatment of HCC. The pathogenesis of HCC involves hyperactivation of several signal pathways and aberrant expression of some key molecules, suggesting combination treatment may yield major improvements in the management of this disease. The emerging sorafenib-based combination treatments are reviewed in the present article.
Publish Date 2015-11-11 13:34
Citation Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070
Url http://www.wjgnet.com/1007-9327/full/v21/i42/12059.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i42.12059
Full Article (PDF) WJG-21-12059.pdf
Full Article (Word) WJG-21-12059.doc
Manuscript File 20414-Review.docx
Answering Reviewers 20414-Answering reviewers.pdf
Audio Core Tip 20414-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 20414-Conflict-of-interest statement.pdf
Copyright License Agreement 20414-Copyright assignment.pdf
Peer-review Report 20414-Peer-review(s).pdf
Scientific Misconduct Check 20414-Scientific misconduct check.pdf
Scientific Editor Work List 20414-Scientific editor work list.pdf